These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10658293)

  • 21. Spironolactone for congestive heart failure.
    Lindbloom EJ; Koenig CJ
    J Fam Pract; 1999 Oct; 48(10):752. PubMed ID: 12224671
    [No Abstract]   [Full Text] [Related]  

  • 22. High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial.
    Schwartz JS; Wang YR; Cleland JG; Gao L; Weiner M; Poole-Wilson PA;
    Am J Manag Care; 2003 Jun; 9(6):417-24. PubMed ID: 12816171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and risk factors of asymptomatic first-dose hypotension with angiotensin-converting enzyme inhibitors in chronic heart failure due to systolic dysfunction.
    Thanikachalam S; Manchanda SC
    Indian Heart J; 2003; 55(2):167-71. PubMed ID: 12921333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omission of drug dose information.
    Hollenberg NK
    Arch Intern Med; 2006 Feb; 166(3):368; author reply 368-9. PubMed ID: 16476880
    [No Abstract]   [Full Text] [Related]  

  • 25. [Angiotensin-converting enzyme inhibitor dosage in chronic heart insufficiency].
    Villadsen HD; Haghfelt T
    Ugeskr Laeger; 1998 Jun; 160(26):3931-2. PubMed ID: 9656837
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.
    Packer M; Poole-Wilson PA; Armstrong PW; Cleland JG; Horowitz JD; Massie BM; Rydén L; Thygesen K; Uretsky BF
    Circulation; 1999 Dec; 100(23):2312-8. PubMed ID: 10587334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of the ATLAS study. High or low doses of ACE inhibitors for heart failure?
    Hobbs RE
    Cleve Clin J Med; 1998; 65(10):539-42. PubMed ID: 9830787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
    Einhorn PT; Davis BR; Massie BM; Cushman WC; Piller LB; Simpson LM; Levy D; Nwachuku CE; Black HR;
    Am Heart J; 2007 Jan; 153(1):42-53. PubMed ID: 17174636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vasodilator therapy in heart failure.
    Kubo SH
    J Heart Lung Transplant; 1994; 13(4):S122-5. PubMed ID: 7947868
    [No Abstract]   [Full Text] [Related]  

  • 30. High dose lisinopril in heart failure: economic considerations.
    Ess SM; Lüscher TF; Szucs TD
    Cardiovasc Drugs Ther; 2002 Jul; 16(4):365-71. PubMed ID: 12652106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Target doses of ACE inhibitors in heart failure: where should we aim?
    Pitt B; Nicklas JM
    Eur Heart J; 1998 Mar; 19(3):370-1. PubMed ID: 9568438
    [No Abstract]   [Full Text] [Related]  

  • 32. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
    Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract]   [Full Text] [Related]  

  • 33. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
    Rapezzi C; Ciliberti P; Graziosi M; Riva L
    Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin-converting enzyme inhibitors or beta-blockers in heart failure: does it matter who goes first?
    Fang JC
    Circulation; 2005 Oct; 112(16):2380-2. PubMed ID: 16230494
    [No Abstract]   [Full Text] [Related]  

  • 35. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
    G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Angiotensin converting enzyme inhibitors in arterial hypertension and cardiac failure. The question of the dose].
    González-Juanatey JR
    Med Clin (Barc); 2000; 114 Suppl 2():24-7. PubMed ID: 10916802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale and design of a randomized trial to assess the effects of beta-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF).
    Hori M; Kitabatake A; Tsutsui H; Okamoto H; Shirato K; Nagai R; Izumi T; Yokoyama H; Yasumura Y; Ishida Y; Matsuzaki M; Oki T; Sekiya M;
    J Card Fail; 2005 Sep; 11(7):542-7. PubMed ID: 16198251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow-up.
    Eveson DJ; Robinson TG; Potter JF
    Am J Hypertens; 2007 Mar; 20(3):270-7. PubMed ID: 17324738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Consequences of ALLHAT: Thiazides rehabilitated--time to change prescription patterns].
    Hernborg A; Håkansson J; Werkö L; Berglund G
    Lakartidningen; 2003 Feb; 100(6):408-10. PubMed ID: 12607432
    [No Abstract]   [Full Text] [Related]  

  • 40. The rationale and indications for angiotensin receptor blockers in heart failure.
    Bybee KA; Das S; O'Keefe JH
    Heart Fail Clin; 2006 Jan; 2(1):81-8. PubMed ID: 17386879
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.